lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma

Figure 10

RP11-838N2.3 overexpression could not affect the cell cycle of A549. (a) A549 OE-NC. (b) A549 OE. (c) A549 OE-NC+2 μg/ml cisplatin. (d) A549 OE+2 μg/ml cisplatin. (e) Compared with the A549 OE-NC group, the A549 OE group in the cell ratio of the G0/G1 phase (, ), S phase (, ), and G2/M phase (, ) showed no significant difference. Under the action of cisplatin, compared with those in the A549 OE-NC+2 μg/ml cisplatin group, the cell ratios in the A549 OE+2 μg/ml cisplatin group in the G0/G1 phase (, ), S phase (, ), and G2/M phase (, ) were not distinctly different.

(a)

(b)

(c)

(d)

(e)